Literature DB >> 17664456

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity.

Howard S Hochster, Axel Grothey, Barrett H Childs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17664456     DOI： 10.1200/JCO.2007.13.5251

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  35 in total

1.  Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice?

Authors:  Kathryn M Field; Suzanne Kosmider; Michael Jefford; Ross Jennens; Michael Green; Peter Gibbs
Journal:  J Oncol Pract       Date:  2008-11       Impact factor: 3.840

2.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

Authors:  Axel Grothey; Daniel A Nikcevich; Jeff A Sloan; John W Kugler; Peter T Silberstein; Todor Dentchev; Donald B Wender; Paul J Novotny; Umesh Chitaley; Steven R Alberts; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

3.  Accomplishments in 2007 in the treatment of advanced colorectal cancer.

Authors:  Richard M Goldberg; Alfredo Carrato
Journal:  Gastrointest Cancer Res       Date:  2008-05

4.  Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.

Authors:  Lin Li; Jinxiu Li; Yan Zuo; Danny Dang; Jeffrey A Frost; Qing Yang
Journal:  J Pain       Date:  2018-11-22       Impact factor: 5.820

5.  Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

Authors:  Rhonda J Moore; Hunter Groninger
Journal:  Cureus       Date:  2013-06-14

6.  The search for treatments to reduce chemotherapy-induced peripheral neuropathy.

Authors:  Deirdre R Pachman; Charles L Loprinzi; Axel Grothey; Lauren E Ta
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

7.  Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.

Authors:  Eiji Oki; Yasunori Emi; Hiroshi Kojima; Jun Higashijima; Takeshi Kato; Yasuhiro Miyake; Masanori Kon; Yutaka Ogata; Kenichi Takahashi; Hideyuki Ishida; Hiroshi Saeki; Yoshihisa Sakaguchi; Takeharu Yamanaka; Toru Kono; Naohiro Tomita; Hideo Baba; Ken Shirabe; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2015-01-28       Impact factor: 3.402

8.  Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).

Authors:  Charles L Loprinzi; Rui Qin; Shaker R Dakhil; Louis Fehrenbacher; Kathleen A Flynn; Pamela Atherton; Drew Seisler; Rubina Qamar; Grant C Lewis; Axel Grothey
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

Review 9.  Neurological adverse effects caused by cytotoxic and targeted therapies.

Authors:  David Schiff; Patrick Y Wen; Martin J van den Bent
Journal:  Nat Rev Clin Oncol       Date:  2009-08-25       Impact factor: 66.675

10.  Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.

Authors:  Jason A Sprowl; Giuliano Ciarimboli; Cynthia S Lancaster; Hugh Giovinazzo; Alice A Gibson; Guoqing Du; Laura J Janke; Guido Cavaletti; Anthony F Shields; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.